261 related articles for article (PubMed ID: 37450602)
1. An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV.
Mystakelis HA; Wilson E; Laidlaw E; Poole A; Krishnan S; Rupert A; Welker JL; Gorelick RJ; Lisco A; Manion M; Baker JV; Migueles SA; Sereti I
AIDS; 2023 Oct; 37(12):1827-1835. PubMed ID: 37450602
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
Ghati N; Roy A; Bhatnagar S; Bhati S; Bhushan S; Mahendran M; Thakur A; Tiwari P; Dwivedi T; Mani K; Gupta R; Mohan A; Garg R; Saxena A; Guleria R; Deepti S
Trials; 2020 Oct; 21(1):902. PubMed ID: 33126910
[TBL] [Abstract][Full Text] [Related]
3. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
4. Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.
Probasco JC; Spudich SS; Critchfield J; Lee E; Lollo N; Deeks SG; Price RW
Neurology; 2008 Aug; 71(7):521-4. PubMed ID: 18695163
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
Nakanjako D; Ssinabulya I; Nabatanzi R; Bayigga L; Kiragga A; Joloba M; Kaleebu P; Kambugu AD; Kamya MR; Sekaly R; Elliott A; Mayanja-Kizza H
Trop Med Int Health; 2015 Mar; 20(3):380-90. PubMed ID: 25441397
[TBL] [Abstract][Full Text] [Related]
6. Plasma Levels of C-Type Lectin REG3α and Gut Damage in People With Human Immunodeficiency Virus.
Isnard S; Ramendra R; Dupuy FP; Lin J; Fombuena B; Kokinov N; Kema I; Jenabian MA; Lebouché B; Costiniuk CT; Ancuta P; Bernard NF; Silverman MS; Lakatos PL; Durand M; Tremblay C; Routy JP;
J Infect Dis; 2020 Jan; 221(1):110-121. PubMed ID: 31504638
[TBL] [Abstract][Full Text] [Related]
7. HIV-DNA content in pTfh cells is associated with residual viremia in elite controllers.
García M; Morcilla V; Navarrete-Muñoz MÁ; Fisher K; Cabello A; López-Bernaldo JC; De La Hera F; Barros C; Fernández-Guerrero M; Estrada V; Górgolas M; Benito JM; Palmer S; Rallón N
AIDS; 2021 Mar; 35(3):393-398. PubMed ID: 33252487
[TBL] [Abstract][Full Text] [Related]
8. Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression.
Gisslen M; Keating SM; Spudich S; Arechiga V; Stephenson S; Zetterberg H; Di Germanio C; Blennow K; Fuchs D; Hagberg L; Norris PJ; Peterson J; Shacklett BL; Yiannoutsos CT; Price RW
PLoS One; 2021; 16(5):e0250987. PubMed ID: 33983973
[TBL] [Abstract][Full Text] [Related]
9. High residual inflammation despite HIV viral suppression: Lessons learned from real-time adherence monitoring among people with HIV in Africa.
Castillo-Mancilla JR; Musinguzi N; Asiimwe S; Siedner MJ; Orrell C; Bangsberg DR; Haberer JE
HIV Med; 2022 May; 23(5):465-473. PubMed ID: 34704355
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir Size.
Rasmussen TA; Ahuja SK; Kuwanda L; Vjecha MJ; Hudson F; Lal L; Rhodes A; Chang J; Palmer S; Auberson-Munderi P; Mugerwa H; Wood R; Badal-Faesen S; Pillay S; Mngqibisa R; LaRosa A; Hildago J; Petoumenos K; Chiu C; Lutaakome J; Kitonsa J; Kabaswaga E; Pala P; Ganoza C; Fisher K; Chang C; Lewin SR; Wright EJ
Clin Infect Dis; 2022 Nov; 75(10):1781-1791. PubMed ID: 35396591
[TBL] [Abstract][Full Text] [Related]
11. The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy.
Ekwaru JP; Campbell J; Malamba S; Moore DM; Were W; Mermin J
J Int AIDS Soc; 2013 Apr; 16(1):17355. PubMed ID: 23547778
[TBL] [Abstract][Full Text] [Related]
12. Rapid development of HIV elite control in a patient with acute infection.
Morley D; Lambert JS; Hogan LE; De Gascun C; Redmond N; Rutishauser RL; Thanh C; Gibson EA; Hobbs K; Bakkour S; Busch MP; Farrell J; McGetrick P; Henrich TJ
BMC Infect Dis; 2019 Sep; 19(1):815. PubMed ID: 31533639
[TBL] [Abstract][Full Text] [Related]
13. CD4+ T-cell Count may not be a Useful Strategy to Monitor Antiretroviral Therapy Response in HTLV-1/HIV Co-infected Patients.
Vandormael A; Rego F; Danaviah S; Carlos Junior Alcantara L; Boulware DR; de Oliveira T
Curr HIV Res; 2017; 15(3):225-231. PubMed ID: 28215175
[TBL] [Abstract][Full Text] [Related]
14. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
Dubé MP; Chan ES; Lake JE; Williams B; Kinslow J; Landay A; Coombs RW; Floris-Moore M; Ribaudo HJ; Yarasheski KE
Clin Infect Dis; 2019 Sep; 69(7):1165-1172. PubMed ID: 30535188
[TBL] [Abstract][Full Text] [Related]
16. Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy.
Hsu DC; Kerr SJ; Thongpaeng P; Iampornsin T; Pett SL; Zaunders JJ; Avihingsanon A; Ubolyam S; Ananworanich J; Kelleher AD; Cooper DA
J Infect; 2014 Apr; 68(4):344-54. PubMed ID: 24325926
[TBL] [Abstract][Full Text] [Related]
17. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda.
Jain V; Byonanebye DM; Amanyire G; Kwarisiima D; Black D; Kabami J; Chamie G; Clark TD; Rooney JF; Charlebois ED; Kamya MR; Havlir DV;
AIDS; 2014 Sep; 28(15):2241-9. PubMed ID: 25022596
[TBL] [Abstract][Full Text] [Related]
18. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.
Mermin J; Ekwaru JP; Were W; Degerman R; Bunnell R; Kaharuza F; Downing R; Coutinho A; Solberg P; Alexander LN; Tappero J; Campbell J; Moore DM
BMJ; 2011 Nov; 343():d6792. PubMed ID: 22074711
[TBL] [Abstract][Full Text] [Related]
19. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
20. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
